

May 17, 2023

Via EDGAR

U.S. Securities and Exchange Commission  
Division of Corporation Finance  
100 F Street, N.E.  
Mail Stop 4546  
Washington, D.C. 20549

Attn: Lauren S. Hamill

Re: **Clearside Biomedical, Inc.**  
**Registration Statement on Form S-3**  
**File No. 333-271902**

**Acceleration Request**

**Requested Date: May 19, 2023**  
**Requested Time: 4:00 P.M. Eastern Time**

Ladies and Gentlemen:

In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the "**Registrant**") hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-271902) (the "**Registration Statement**") to become effective on May 19, 2023, at 4:00 p.m. Eastern Time, or as soon thereafter as is practicable, or at such later time as the Registrant may orally request via telephone call to the staff.

Once the Registration Statement has been declared effective, please orally confirm that event with Mark Ballantyne of Cooley LLP, counsel to the Registrant, at (703) 456-8084, or in his absence, Asheley Walker at (202) 842-7856.

*[Signature page follows]*

---

Very truly yours,

Clearside Biomedical, Inc.

By: /s/ Charles A. Deignan  
Charles A. Deignan  
*Chief Financial Officer*

cc: George Lasezkay, Clearside Biomedical, Inc.  
Mark Ballantyne, Cooley LLP  
Asheley Walker, Cooley LLP